journal
MENU ▼
Read by QxMD icon Read
search

Pediatric Blood & Cancer

journal
https://www.readbyqxmd.com/read/29676506/high-dose-chemotherapy-without-whole-lung-radiation-for-refractory-pulmonary-metastases-in-an-infant-with-stage-iv-favorable-histology-wilms-tumor
#1
LETTER
Haruko Shima, Yuji Yamada, Hiroshi Asanuma, Hiroyuki Shimada
No abstract text is available yet for this article.
April 20, 2018: Pediatric Blood & Cancer
https://www.readbyqxmd.com/read/29667785/radiation-necrosis-following-proton-therapy-successfully-treated-by-low-dose-bevacizumab-in-a-patient-with-relapsed-anaplastic-ependymoma
#2
LETTER
Shoji Saito, Yosuke Miyairi, Masayuki Araya, Shoji Yomo, Haruki Kuwabara, Eriko Uchida, Tatsuo Watanabe, Takashi Kurata, Kazuo Sakashita, Hiroaki Shigeta
No abstract text is available yet for this article.
April 18, 2018: Pediatric Blood & Cancer
https://www.readbyqxmd.com/read/29667775/views-of-parents-of-children-with-sickle-cell-disease-on-pre-implantation-genetic-diagnosis
#3
Isha Darbari, Jeanne E O'Brien, Steven J Hardy, Barbara Speller-Brown, Lisa Thaniel, Brenda Martin, Deepika S Darbari, Robert S Nickel
Pre-implantation genetic diagnosis (PGD) is an option for parents who have a child with sickle cell disease (SCD) to have another child without SCD. We conducted a survey of 19 parents with at least one child with SCD to investigate views on PGD. Before education, 44% of parents were aware of PGD. All parents rated PGD education as important. All parents considering another child also reported interest in using PGD if insurance covered its costs. Parents who have a child with SCD appear to be interested in PGD and educational tools informing this group about PGD should be developed...
April 18, 2018: Pediatric Blood & Cancer
https://www.readbyqxmd.com/read/29667774/patient-with-proteus-syndrome-and-paratesticular-ovarian-type-papillary-serous-carcinoma
#4
LETTER
Alina Sadaf, Angela Nguyen, Arthur B Meyers, Chi K Nguyen, Mark A Wehry, Roger Berkow
No abstract text is available yet for this article.
April 18, 2018: Pediatric Blood & Cancer
https://www.readbyqxmd.com/read/29667766/role-of-clinical-trials-in-survival-progress-of-american-adolescents-and-young-adults-with-cancer-and-lack-thereof
#5
Archie Bleyer, Eric Tai, Stuart Siegel
In the United States, adolescent and young adult (AYA) patients with cancer have the lowest clinical trial participation rate of all age groups and slower progress in survival improvement than younger patients. Ominously, AYA clinical trial participation has been steadily decreasing since 2010, except in 15-19 year olds and AYAs with acute lymphoblastic leukemia. In order to reverse the accrual trend, multiple changes are necessary, including convincing community oncologists to pursue clinical trials on behalf of their AYA patients and to have the new National Community Oncology Research Program and National Clinical Trials Network lead a coordinated effort to increase accrual...
April 18, 2018: Pediatric Blood & Cancer
https://www.readbyqxmd.com/read/29667765/molecular-profile-of-inflammatory-and-megakaryocytic-factors-in-pediatric-myelodysplastic-syndrome-with-acute-myelofibrosis
#6
Kais Hussein, Meinolf Suttorp, Angelika Stucki-Koch, Irith Baumann, Charlotte M Niemeyer, Hans Kreipe
Pediatric fibrotic myelodysplastic syndromes (ped-MDS-MF) and pediatric primary myelofibrosis (ped-PMF) are rare, and the molecular changes which mediate fibrosis have never been investigated. Histology and gene expression profile of 119 fibrosis/angiogenesis/inflammation/megakaryopoiesis-related factors in bone marrow biopsies were performed (two ped-MDS-MF and one ped-PMF). In one progressive ped-MDS, comparison of MF grade 0 (no myelofibrosis) and MF grade 2 (dense network of reticulin fibres) after 4 months showed that expression of fibrosis-related transcripts increased and dysplastic megakaryocytes formed a dense net of CD42b+ proplatelets...
April 18, 2018: Pediatric Blood & Cancer
https://www.readbyqxmd.com/read/29667755/spontaneous-intramedullary-hematoma-and-leukemic-deposit-in-spinal-cord-causing-acute-onset-paraplegia-in-a-child-with-acute-lymphoblastic-leukemia
#7
LETTER
Kaduveettil Gopinathan Gopakumar, Binitha Rajeswari, Rumesh Chandar, Ramachandran Krishnankutty Nair, Priyakumari Thankamony
No abstract text is available yet for this article.
April 18, 2018: Pediatric Blood & Cancer
https://www.readbyqxmd.com/read/29667750/association-between-body-mass-index-and-pancreatitis-in-children-with-acute-lymphoblastic-leukemia
#8
Pernille R Mogensen, Benjamin O Wolthers, Kathrine Grell, Kjeld Schmiegelow, Thomas L Frandsen
No abstract text is available yet for this article.
April 18, 2018: Pediatric Blood & Cancer
https://www.readbyqxmd.com/read/29667725/parent-centered-communication-at-time-of-pediatric-cancer-diagnosis-a-systematic-review
#9
REVIEW
Cristiana Hentea, Erika R Cheng, Nerissa S Bauer, Emily L Mueller
There are limited data focused on parental communication needs surrounding the time when a child is diagnosed with cancer. In this systematic review, we synthesized current literature on communication preferences of parents at the time of their child's diagnosis of cancer. We identified 16 studies that yielded 4 major themes parents recognized as important: communication style, content, logistics, and healthcare team. We further identified several concepts that inform parent-centered communication practice...
April 18, 2018: Pediatric Blood & Cancer
https://www.readbyqxmd.com/read/29667723/andrea-farkas-patenaude-phd-1946-2018
#10
Lori Wiener, Robert B Noll
No abstract text is available yet for this article.
April 18, 2018: Pediatric Blood & Cancer
https://www.readbyqxmd.com/read/29667722/acute-myelogenous-leukemia-in-adolescents-and-young-adults
#11
REVIEW
Ursula Creutzig, Matthew A Kutny, Ronald Barr, Richard F Schlenk, Raul C Ribeiro
The incidence of acute myelogenous leukemia (AML) increases progressively with age. Favorable genetic mutations are most prevalent in children, and unfavorable profiles increase proportionately in adolescents and young adults (AYA) and into later adulthood. Survival rates of AYA have improved over recent decades to 50-60%, but their accrual to clinical trials remains poor. In contrast to AYA with acute lymphoblastic leukemia, the prognostic benefit for AYA with AML enrolled in pediatric compared with adult trials is minor and only seen when different protocols are used...
April 18, 2018: Pediatric Blood & Cancer
https://www.readbyqxmd.com/read/29667721/diverse-manifestations-of-acute-sickle-cell-hepatopathy-in-pediatric-patients-with-sickle-cell-disease-a-case-series
#12
Lydia H Pecker, Nidhi Patel, Susan Creary, Anil Darbari, Emily Riehm Meier, Deepika S Darbari, Ross M Fasano
The hepatic complications of sickle cell disease (SCD) are associated with increased morbidity and mortality in adults; children usually survive but may suffer significant sequelae. Few diagnostic tools differentiate the various hepatic manifestations of SCD. Why patients exhibit one hepatic pathology versus another is unclear. We report four pediatric patients with hemoglobin SS disease with diverse manifestations of acute hepatic involvement including acute sickle hepatic crisis, hepatic sequestration, sickle cell intrahepatic cholestasis, and a non-SCD cause of hepatopathy in a patient with viral hepatitis...
April 18, 2018: Pediatric Blood & Cancer
https://www.readbyqxmd.com/read/29667720/mycophenolate-mofetil-administered-every-8-hours-in-combination-with-tacrolimus-is-efficacious-in-the-prophylaxis-of-acute-graft-versus-host-disease-in-childhood-adolescent-and-young-adult-allogeneic-stem-cell-transplantation-recipients
#13
Olga Militano, Mehmet F Ozkaynak, Brinda Mehta, Carmella van deVen, Carl Hamby, Mitchell S Cairo
BACKGROUND: The optimal dose and schedule of mycophenolate mofetil (MMF) in pediatric allogeneic stem cell transplant recipients remains to be determined. We previously reported safety and pharmacokinetics of MMF at 900 mg/m2 q6h dosing. This study was conducted to investigate the efficacy of tacrolimus plus q8h MMF dosing for acute graft versus host disease (GVHD) prophylaxis in a heterogeneous population of children, adolescent, young adult allogeneic stem cell transplant recipients, utilizing multiple allogeneic donor sources...
April 18, 2018: Pediatric Blood & Cancer
https://www.readbyqxmd.com/read/29644793/who-does-she-think-she-is
#14
Leslie S Kersun
No abstract text is available yet for this article.
April 11, 2018: Pediatric Blood & Cancer
https://www.readbyqxmd.com/read/29637700/efficacy-and-safety-of-administering-pediatric-treatment-to-adolescent-patients-with-mature-b-cell-non-hodgkin-lymphoma-within-the-japanese-pediatric-leukemia-lymphoma-study-group-clinical-trial
#15
Masahiro Sekimizu, Hiroya Hashimoto, Tetsuya Mori, Ryoji Kobayashi, Keizo Horibe, Masahito Tsurusawa
BACKGROUND: Currently, there is no standardized treatment for adolescents, aged 15 years or older, with mature B-cell non-Hodgkin lymphoma (B-NHL), although this age group has been reported to have a poorer prognosis than younger patients. PROCEDURE: The present study analyzed the data of 321 patients with B-NHL, enrolled in a pediatric clinical trial, comparing the treatment outcomes between adolescents (aged 15-18 years, n = 25) and children (≤15 years, n = 297), with a particular focus on the safety and tolerability of administering pediatric regimens to adolescents...
April 10, 2018: Pediatric Blood & Cancer
https://www.readbyqxmd.com/read/29637697/temporal-trends-of-splenectomy-in-pediatric-hospitalizations-with-immune-thrombocytopenia
#16
Neel S Bhatt, Parth Bhatt, Keyur Donda, Fredrick Dapaah-Siakwan, Riddhi Chaudhari, Vijay Gandhi Linga, Bhumi Patel, Anusha Lekshminarayanan, Smita Bhaskaran, Samer Zaid-Kaylani, Sherif M Badawy
BACKGROUND: Splenectomy is considered an effective treatment for immune thrombocytopenia (ITP) with 70-80% response rate. However, its current use is limited in children with ITP. It is unclear if the rates of splenectomy have changed over time. Using a large nationally representative database, we aimed to study the trends of splenectomy in pediatric hospitalizations with ITP, and the factors associated with splenectomy during these encounters. METHODS: Using National (Nationwide) Inpatient Sample (NIS), and international classification of diseases (9th revision), clinical modification (ICD-9-CM) codes, we studied pediatric ITP hospitalizations with occurrence of total splenectomy between 2005 and 2014...
April 10, 2018: Pediatric Blood & Cancer
https://www.readbyqxmd.com/read/29637688/epidemiologic-and-clinical-characteristics-of-nontransfusion-dependent-thalassemia-in-the-united-states
#17
Elliott Vichinsky, Alan Cohen, Alexis A Thompson, Patricia J Giardina, Ashutosh Lal, Carole Paley, Wendy Y Cheng, Nora McCormick, Medha Sasane, Ying Qiu, Janet L Kwiatkowski
BACKGROUND: Nontransfusion-dependent thalassemia (NTDT) refers to a diverse group of thalassemia mutations and clinical phenotypes that do not require chronic transfusions. It is increasingly prevalent in the United States. PROCEDURE: This study reviews the epidemiology and clinical characteristics of 138 patients with NTDT treated at four US thalassemia centers from 1997 to 2014. Data on laboratory results, transfusions, and clinical complications were collected from patient charts...
April 10, 2018: Pediatric Blood & Cancer
https://www.readbyqxmd.com/read/29637687/pediatric-early-warning-systems-aid-in-triage-to-intermediate-versus-intensive-care-for-pediatric-oncology-patients-in-resource-limited-hospitals
#18
Asya Agulnik, Anisha Nadkarni, Lupe Nataly Mora Robles, Dora Judith Soberanis Vasquez, Ricardo Mack, Federico Antillon-Klussmann, Carlos Rodriguez-Galindo
Pediatric oncology patients hospitalized in resource-limited settings are at high risk for clinical deterioration resulting in mortality. Intermediate care units (IMCUs) provide a cost-effective alternative to pediatric intensive care units (PICUs). Inappropriate IMCU triage, however, can lead to poor outcomes and suboptimal resource utilization. In this study, we sought to characterize patients with clinical deterioration requiring unplanned transfer to the IMCU in a resource-limited pediatric oncology hospital...
April 10, 2018: Pediatric Blood & Cancer
https://www.readbyqxmd.com/read/29633496/klinefelter-syndrome-as-a-risk-factor-for-recurrent-deep-vein-thrombosis-in-an-adolescent-male-significance-of-a-thorough-physical-examination
#19
LETTER
Amy E Valasek, Patrick Warren, Riten Kumar
No abstract text is available yet for this article.
April 10, 2018: Pediatric Blood & Cancer
https://www.readbyqxmd.com/read/29630784/proton-therapy-for-central-nervous-system-tumors-in-children
#20
REVIEW
Matthew M Ladra, Shannon M MacDonald, Stephanie A Terezakis
Proton therapy is a form of particle therapy with physical properties that provide a superior dose distribution compared to photons. The ability to spare healthy, developing tissues from low dose radiation with proton therapy is well known. The capability to decrease radiation exposure for children has been lauded as an important advance in pediatric cancer care, particularly for central nervous system (CNS) tumors. Favorable clinical outcomes have been reported and justify the increased cost and burden of this therapy...
April 6, 2018: Pediatric Blood & Cancer
journal
journal
20217
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"